

# Ultroser® G, SF, HY Serum Substitutes

## Description

The present trend of cell biologists is to replace serum (generally fetal calf serum) by better defined and constant substitution media such as **Ultroser G, SF, HY** serum substitutes. The main advantages of these serum substitutes are :

- Semi-defined composition ensuring batch-to-batch biological reproducibility,
- Low protein content,
- Easy use and storage.

**Ultroser** has a concentration 5 times higher than fetal calf serum (2% of reconstituted **Ultroser** are equivalent to 10% of fetal calf serum in the basal medium).

The quality control tests usually performed on Ultroser batches are listed in Table 1.

## Applications

### • Ultroser® G and SF

**Ultroser G** has been successfully used for the culture of numerous anchorage-dependent cells for either basic research or diagnostic purposes. It is particularly useful in prenatal diagnosis for the culture of amniotic cells for karyotyping.

**Ultroser SF** may be used for the culture of adherent cells that require a low steroid medium.

### • Ultroser® HY

**Ultroser HY** is particularly useful for the culture of hybridomas and lymphoblastoid cells. It may replace fetal calf serum for fusion, growth and secretion steps. It does not contain any immunoglobulins nor mitogen lectins.

Hybridomas can be easily cultured with **Ultroser HY** after a short adaptation time at laboratory and industrial scale.

**Table 1. Quality control tests performed on Ultroser G, SF, HY.**

	Ultroser G	Ultroser SF	Ultroser HY
Physicochemical parameters			
- pH	X	X	X
- Protein concentration	X	X	X
Sterility control :			
- Bacteria & fungi	X	X	X
- Bovine viruses (BHV1-DVB/MM, hemadsorbents)	X	X	X
- Mycoplasma	X	X	X
Proliferation capacity	Hep G2	Muscular cells	2 different hybridomas
Secretion of antibodies	-	-	Goat antibody anti-mouse IgM
Karyotyping	X	-	-

## References

- Ultroses G**
1. Calvi S.L. & Maisse G., *Cryobiology* 36 (June 1998) 255.
  2. Sakwe A.M. & Evehe M.S., *Parasite* 4 (1997) 351.
  3. Clouston H.J., et al., *Hum. Genet.* 101 (1997) 30.
  4. Rattner A., et al., *In Vitro Cell Dev. Biol. Anim.* 33 (1997) 757.
  5. Furukawa M., et al., *Am J. Physiol.* 271 (1996) L593.
  6. Monnier Z., Bride M., *Experientia* 51 (1995) 824.
  7. Smit N.P., et al., *Pigment Cell Res.* 8 (1995) 19-27.
  8. Loir M. & Le Gac F., *Biol. Reprod.* 51 (1994) 1154.
  10. Roberts A.J. & Echterkamp S.E., *Biol. Reprod.* 51 (1994) 273.
  11. Hunter I., et al., *J. Cell Sci.* 107 (1994) 1205.
  12. Boué J., et al., *Ann. Génét.* 22 (1979) 3.
  13. Tejada I., et al., *Ann. Génét.* 26 (1983) 247.
  14. Myara I., et al., *Biology of the Cell* 57 (1986) 243.
  15. Schmidt-Jensen S. & Christensen B., Lind A.M., *Prenatal Diagnosis* 9 (1989) 309.
- Ultroses SF**
16. Pinset C., et al., *EMBO Journal* 10 (1991) 2411.
  17. Montarrat D., et al., *New Biologist* 3 (1991) 592.
  18. Pinset C. & Montarras D., *Cell Biology* 1 (1994) 226.
  19. Naffakh N., et al., *Human Gene Therapy* 7 (1996) 11.
  20. Loir M., *Gamete Research* 24 (1989) 151.
  21. Loir M., *Cell Tissue Res.* 261 (1990) 133.
  22. Loir M., *General and Comparative Endocrinology* 78 (1990) 388.
- Ultroses HY**
23. Séné C., et al., *BioSciences* 4 (1985) 145.
  24. Boschetti E. & Séné C., *BioSciences* 5 (1986) 80.
  25. Couillin P., et al., *BioSciences* 5 (1987) 226.

**Table 2. Cells successfully tested with Ultroses G, SF, HY.**

Ultroses G	Ultroses SF	Ultroses HY
Glial cells Rat myocytes Human myocytes Amniotic cells Vero CHO BHK Bone marrow cells Fibroblasts skin cells HeLa MRC-5 Thyroid cells Chondrocytes Arterial cells Leydig cells Lewis cells Chicken fibroblasts Promyelocytes HL60 Raji P3HR1 Astrocytes Erythroblasts Hypothalamic cells Keratinocytes	Trout sertoli cells Testis trout cells Myocytes (rat aortic smooth muscle cells) Sol 8 mouse muscle cell lines Modified skeletal muscles Muscle cell lines from dog, mouse, human	Myeloma : - SP2/O - P3 x 63 Ag 8 - P3 x 63 Ag 8653 - P3 - NS 1/1 Ag 4-1 - 210-RCY3-Ag1  Hybridomas: - IH8-4      - EJ 16 - 1 BL7-2   - E12-1 - II CR-10   - E G9-11 - III BZ-24   - 1 BA 12 - CN 9528  Lymphoblastoid cell lines: - LL 80-LL 106 - LL 13 - LL 60 - LL 62 - LL 23 - Daudi - HL 60

## Ordering Information

Product	Pack size	Part Number
Ultroses G (lyophilized)	20 mL	15950-017
Ultroses SF (frozen)	10x10 mL	12039-012
Ultroses HY (lyophilized)	20 mL	66029-018
Ultroses HY (frozen)	400 mL	12038-022



Ultroses G serum substitute is CE mark-certified.



**New York - USA**  
+1 516.484.5400 phone  
+1 516.801.9548 fax  
pharmafilter@pall.com

**Portsmouth - UK**  
+44 (0)23 9230 3303 phone  
+44 (0)23 9230 2506 fax  
BioPharmUK@europe.pall.com

**Cergy - France**  
Pall BioSeptra  
+33 (0)1 34 20 78 00 phone  
+33 (0)1 34 20 78 78 fax  
biosepra@pall.com

[www.pall.com/biopharmaceutical](http://www.pall.com/biopharmaceutical)

**PALL**, Pall, BioSeptra, Ultroses are trademarks of Pall Corporation.  
**Filtration. Separation. Solution.** is a service mark of Pall Corporation.  
 ® indicates a trademark registered in the U.S.  
 © Pall Corporation 2005